377 related articles for article (PubMed ID: 6197336)
1. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
Mayer JH; Tomlinson DR
Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
[TBL] [Abstract][Full Text] [Related]
2. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
Tomlinson DR; Moriarty RJ; Mayer JH
Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
[TBL] [Abstract][Full Text] [Related]
3. Reversal of deficits in axonal transport and nerve conduction velocity by treatment of streptozotocin-diabetic rats with myo-inositol.
Tomlinson DR; Mayer JH
Exp Neurol; 1985 Aug; 89(2):420-7. PubMed ID: 2410289
[TBL] [Abstract][Full Text] [Related]
4. Slow component-a of axonal transport, nerve myo-inositol, and aldose reductase inhibition in streptozocin-diabetic rats.
Tomlinson DR; Sidenius P; Larsen JR
Diabetes; 1986 Apr; 35(4):398-402. PubMed ID: 2420664
[TBL] [Abstract][Full Text] [Related]
5. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
Gillon KR; Hawthorne JN; Tomlinson DR
Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
[TBL] [Abstract][Full Text] [Related]
6. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
Cameron NE; Cotter MA; Robertson S
Q J Exp Physiol; 1989 Nov; 74(6):917-26. PubMed ID: 2512591
[TBL] [Abstract][Full Text] [Related]
7. Treatment with an aldose reductase inhibitor can reduce the susceptibility of fast axonal transport following nerve compression in the streptozotocin-diabetic rat.
Dahlin LB; Archer DR; McLean WG
Diabetologia; 1987 Jun; 30(6):414-8. PubMed ID: 2445613
[TBL] [Abstract][Full Text] [Related]
8. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
[TBL] [Abstract][Full Text] [Related]
9. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
[TBL] [Abstract][Full Text] [Related]
10. Prevention of defects of axonal transport in experimental diabetes by aldose reductase inhibitors.
Tomlinson DR; Willars GB; Robinson JP
Drugs; 1986; 32 Suppl 2():15-8. PubMed ID: 2431858
[TBL] [Abstract][Full Text] [Related]
11. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
[TBL] [Abstract][Full Text] [Related]
12. Essential fatty acid treatment--effects on nerve conduction, polyol pathway and axonal transport in streptozotocin diabetic rats.
Tomlinson DR; Robinson JP; Compton AM; Keen P
Diabetologia; 1989 Sep; 32(9):655-9. PubMed ID: 2477293
[TBL] [Abstract][Full Text] [Related]
13. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
Cameron NE; Cotter MA; Dines KC; Maxfield EK; Carey F; Mirrlees DJ
Diabetologia; 1994 Jul; 37(7):651-63. PubMed ID: 7958535
[TBL] [Abstract][Full Text] [Related]
14. Slow orthograde axonal transport of radiolabelled protein in sciatic motoneurones of rats with short-term experimental diabetes: effects of treatment with an aldose reductase inhibitor or myo-inositol.
Mayer JH; Tomlinson DR; McLean WG
J Neurochem; 1984 Nov; 43(5):1265-70. PubMed ID: 6208327
[TBL] [Abstract][Full Text] [Related]
15. Effect of aldose reductase inhibition on nerve conduction velocity and resistance to ischemic conduction block in experimental diabetes.
Price DE; Airey CM; Alani SM; Wales JK
Diabetes; 1988 Jul; 37(7):969-73. PubMed ID: 3133261
[TBL] [Abstract][Full Text] [Related]
16. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
Hirata Y; Fujimori S; Okada K
Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
[TBL] [Abstract][Full Text] [Related]
17. Reduced anterograde and retrograde accumulation of axonally transported phosphofructokinase in streptozotocin-diabetic rats: effects of insulin and the aldose reductase inhibitor 'Statil'.
Willars GB; Calcutt NA; Tomlinson DR
Diabetologia; 1987 Apr; 30(4):239-43. PubMed ID: 2439402
[TBL] [Abstract][Full Text] [Related]
18. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
19. Fast anterograde axonal transport in wasted and non-wasted diabetic rats; effects of aldose reductase inhibition.
Whiteley SJ; Townsend J; Tomlinson DR; Willars GB
Diabetes Res; 1986 Nov; 3(9):447-52. PubMed ID: 2435444
[TBL] [Abstract][Full Text] [Related]
20. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
Stevens MJ; Lattimer SA; Kamijo M; Van Huysen C; Sima AA; Greene DA
Diabetologia; 1993 Jul; 36(7):608-14. PubMed ID: 8359577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
